Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

NTLA 10.31.2024

Full Press ReleaseSEC FilingsOur NTLA Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
  • 01.13.2025 - J.P. Morgan Healthcare Conference
  • 01.09.2025 - Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Recent Filings

  • 01.10.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 8-K Current report
  • 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • Third quarter 2024 financial results –November 7, at8 a.m. ET
  • New clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis –November 16, at11 a.m. CT/12 p.m. ET

CAMBRIDGE, Mass.,Oct. 31, 2024(GLOBE NEWSWIRE) --Intellia Therapeutics, Inc.(NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November.

Third Quarter 2024 Earnings –November 7, at8 a.m. ETIntellia will present its third quarter 2024 financial results and operational highlights.

  • To join the call,U.S.callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726 approximately five minutes before the call. All participants should ask to be connected to theIntellia Therapeuticsconference call.
  • Please visit thislinkfor a simultaneous live webcast of the call.

Clinical Data Update from Phase 1 Study of nex-z –November 16, at11 a.m. CT/12 p.m. ET

Intellia will also host an investor webcast to review new data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z, also known as NTLA-2001), following a late-breaking oral presentation at the 2024American Heart Association(AHA) Scientific Sessions, taking placeNovember 16-18inChicago, Illinois. Nex-z is an investigationalin vivoCRISPR-based gene editing therapy designed to be a single-dose treatment for transthyretin (ATTR) amyloidosis. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron.

  • To join the webcast, please visit thislink, or the Events and Presentations page of the Investors & Media section of the company’s website atwww.intelliatx.com.

A replay of the events will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website atwww.intelliatx.comfor at least 30 days following the event.

AboutIntellia Therapeutics

Intellia Therapeutics, Inc.(NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’sin vivoprograms use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’sex vivoprograms use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more atintelliatx.comand follow us@intelliatx.

Intellia Contacts:

Investors:Lina LiSenior Director, Investor Relations and Corporate Communicationslina.li@intelliatx.com

Media:Matt CrensonTenBridge Communications+1-917-640-7930media@intelliatx.commcrenson@tenbridgecommunications.com

This press release was published by a CLEAR® Verified individual.

Primary Logo

Source: Intellia Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com